I don't think the issue is that simple. For example, a Lyme disease vaccine was pulled from the market over dubious safety issues [1]: > This panel, described

I don't think the issue is that simple. For example, a Lyme disease vaccine was pulled from the market over dubious safety issues [1]: > This panel, described by one participant as raucous and riotous [35], provided a forum for all of the stakeholders [36]. In support of the vaccine, the FDA summarized the VAERS data and concluded that the evidence did not support a causative association. The vaccine manufacturer, now GlaxoSmithKline following a corporate merger, assured the assembled parties that the LYMErix™ vaccine did not cause harm to its recipients. They reviewed the status of their phase IV post-marketing surveillance. Practising physicians spoke of vaccine efficacy by describing the dramatic reduction in Lyme disease cases in their own practices. > Others raised concerns about the vaccine's safety. Scientists argued a potential role for genetic susceptibility and OspA-related autoimmunity in vaccine complications. Poignant presentations by several ‘vaccine victims’ described in detail their suffering. The prosecuting lawyers for the largest class action suit claimed that manufacturers suppressed reports of adverse events from the licensing trial and provided inadequate warnings to genetically susceptible individuals. > After hearing compelling testimonies from all the interested parties, the panel concluded the benefits of LYMErix™ continued to outweigh its risks. The panel made no changes to the product's labelling or indications. However, the FDA required the manufacturer to provide more vaccine safety and efficacy data by increasing the enrolment in their ongoing phase IV trial. The LYMErix™ vaccine remained available for public use. > Market withdrawal > Spawned by the press coverage of vaccine risks and the ongoing litigation, vaccine sales fell off dramatically in 2001. On 26 February 2002 GlaxoSmithKline decided to withdraw LYMErix™ from the market citing poor market performance [37]. > On 9 July 2003 the pharmaceutical giant settled the class action suits with Sheller, Ludwig & Bailey as well as several other smaller law firms. The final agreement included over 1 million dollars in legal fees for the prosecuting lawyers, but provided no financial compensation to the ‘vaccine victims’. The plaintiffs’ attorneys stated that the voluntary removal of LYMErix™ from the market accomplished the main goal of the suit. Despite the settlement, the manufacturer continued to deny that LYMErix™ caused harm and indicated that the decision to settle represented a choice based on economic concerns (i.e. the desire to avoid the costs of lengthy litigation) for a product showing relatively poor performance in the market. 1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2870557/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2870557/